Tazomeline

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tazomeline
Tazomeline.png
Systematic (IUPAC) name
5-[4-(hexylsulfanyl)-1,2,5-thiadiazol-3-yl]-1-methyl-1,2,3,6-tetrahydropyridine
Clinical data
Legal status ?
Identifiers
CAS number 131987-54-7
ATC code None
PubChem CID 131460
ChemSpider 116193
UNII QDP6S14W5W YesY
ChEMBL CHEMBL131819
Chemical data
Formula C14H23N3S2 
Mol. mass 297.48 g/mol

Tazomeline (LY-287,041) is a drug which acts as a non-selective muscarinic acetylcholine receptor agonist.[1][2] It was in clinical trials for the treatment of cognitive dysfunction such as that seen in Alzheimer's disease and schizophrenia, but development was apparently scrapped for unknown reasons.[1][2][3]

See also[edit]

References[edit]

  1. ^ a b Langmead CJ, Watson J, Reavill C (February 2008). "Muscarinic acetylcholine receptors as CNS drug targets". Pharmacology & Therapeutics 117 (2): 232–43. doi:10.1016/j.pharmthera.2007.09.009. PMID 18082893. 
  2. ^ a b Amos D Korczyn (October 2000). "Muscarinic M1 Agonists in the Treatment of Alzheimer's Disease". Expert Opinion on Investigational Drugs 9 (10): 2259–2267(9). doi:10.1517/13543784.9.10.2259. 
  3. ^ Mashkovskii MD, Glushkov RG (April 2001). "Drugs for the Treatment of Alzheimer's Disease". Pharmaceutical Chemistry Journal 35 (4): 179–182. doi:10.1023/A:1010474325601.